Fungal Infection Clinical Trial
Official title:
Open Label, Limited Access Protocol of Posaconazole in Invasive Fungal Infections Study PO2095
Therapeutic options for serious fungal infections are limited by intrinsic and acquired
resistance to existing antifungal agents. For example, zygomycetes (such as Mucor spp.) are
intrinsically resistant to voriconazole and caspofungin. Yet, the only available therapeutic
option, amphotericin, is associated with significant renal toxicity, even in lipid
formulations. Posaconazole is a new antifungal drug, not yet Food and Drug Administration
(FDA) approved, but which has excellent in vitro activity against some intrinsically
resistant fungi such as the zygomycetes.
The intent of this trial is to provide access to posaconazole to patients with serious
fungal infections which are refractory to standard antifungal therapies or invasive fungal
infections for which there are currently no effective therapies. Secondly, the drug will
also be made available to patients with invasive fungal infections who:
- have experienced serious or severe toxicities while receiving standard antifungal
therapies;
- have pre-existing renal dysfunction which precludes use of standard antifungal
therapies; or
- are chronically immunosuppressed with a history of invasive fungal infections
previously treated with posaconazole in other clinical trials, and who require oral
antifungal suppressive therapy as maintenance treatment to prevent recurrence.
This is a multicenter, open-label, non-comparative experimental treatment use protocol. The
experimental treatment use protocol will provide the investigational medication posaconazole
where no other drug is commercially available. Posaconazole is given as an orally or
enterally administered suspension. The duration of therapy is at the discretion of the
investigator. Safety assessments will include an electrocardiogram [ECG] (to ensure no QTc
interval prolongation) performed at baseline and serum/urine pregnancy testing performed at
baseline and every three months after initiation of therapy. Plasma concentrations will be
obtained if there is evidence of clinical failure. No other tests will be performed
specifically for the experimental treatment use protocol.
This is an open-label, multi-center limited access experimental treatment use protocol of
Posaconazole in the treatment of Invasive Fungal Infections. This experimental treatment use
protocol is projected to begin enrollment in September 2001.
Screening:
1. complete medical history, including a review of the subject's fungal infection and the
antifungal treatment(s)
2. women of childbearing potential, will have a serum (blood) or urine pregnancy test
before the experimental medication (posaconazole) is administered. This test requires a
sample of blood to be drawn (10 mL or 1 tablespoon of blood or about 10 ml or 1
tablespoon of urine). The subject will not be able to participate in this experimental
treatment use protocol if pregnant. In addition, while participating in this
experimental treatment use protocol, women of childbearing potential, will have serum
(blood) or urine pregnancy tests performed every 3 months.
3. Electrocardiogram- ECG
The total time for all these screening tests will be one hour and will be carried out in the
subject's hospital room.
Experimental Procedures: the following procedures that are not part of the subject's
standard medical care. This experimental treatment use protocol will be conducted worldwide.
This experimental treatment use protocol is open ended so no set subject enrollment has been
set by Schering Plough. It is anticipated that sites may be opened for a single patient, and
we anticipate enrolling up to two patients at UPMC. All subjects enrolled in this open-label
experimental treatment use protocol will receive treatment with posaconazole as outlined
previously. Subject identification numbers will be assigned sequentially within each site
starting with Subject No. 1. There will be no randomization. Primary efficacy endpoint is
the global response (microbiological and clinical) at the end of therapy.
Review of Inclusion/Exclusion Criteria, Medical/Disease History will be performed at
Baseline. A standard 12-lead ECG will be performed at Baseline Visit or within one week
prior to treatment, and at one month after the initiation of treatment. ECG will be repeated
for any QTc > 450 msec for men or > 470 msec for women, or for any new cardiac signs or
symptoms as clinically indicated. Apart from the ECG and pregnancy test, no other laboratory
testing will be performed solely for the experimental treatment use protocol. Laboratory
abnormalities which represent any clinically significant change from the baseline value (ie,
a change by one toxicity grade or more) at any time during the experimental treatment use
protocol period (active treatment or follow-up), which have clinical manifestations, or
which require an intervention will be considered an adverse event and will be reported to
the sponsor).
Baseline evaluations will be performed within 72 hours prior to the start of the
investigational medication.
The investigational medication (posaconazole) will be dispensed upon completion of the
Baseline assessment once there is confirmation that the Inclusion/Exclusion Criteria are
met. Posaconazole is supplied as suspension 40 mg/mL (105 mL/bottle).
For seriously ill patients, posaconazole will be initially administered at a dose of 200 mg
four times daily (QID) orally/enterally with meals or nutritional supplements, then once
stable the regimen may be changed to 400 mg orally/enterally twice daily (BID). (Changes in
dosing regimen will be at the discretion of the investigator, based on the clinical state of
the patient.) Stable, ambulatory patients may be started on 400 mg PO BID. For subjects who
are receiving enteral feeding, medication will be administered every six hours (QID) or
every 12 hours (BID) as indicated above.
Duration of Treatment: The investigator should use discretion in determining the appropriate
duration of therapy for an individual subject. Duration should be based on the following:
clinical diagnosis of the invasive fungal infection; causative fungal pathogen; severity of
the invasive fungal infection; severity of the subject's underlying disease; recovery from
immune suppression; and rapidity of clinical response.
When the subject is discharged from the hospital, the participant will be given a supply of
investigational medication (posaconazole), which will be adequate to last until the next
doctor's visit. Re-supply of posaconazole will be provided at regular intervals as long as
the subject completes scheduled doctor visits and continues to comply with taking
posaconazole as requested, to receive maximum potential effect of the experimental
medication. The experimental medication should be taken with a full meal in order to be well
absorbed into the blood stream. If the medication is not well absorbed, it may be less
effective.
The experimental treatment use protocol physician will examine the subject at regular
scheduled clinical visits during this experimental treatment use protocol, to determine how
well the subject is responding to and evaluate how well the subject is tolerating
Posaconazole (SCH 56592). No extra visits are required for this experimental treatment
protocol.
Specially trained pharmacists at UPMC will prepare the investigational medication. The
medication will be supplied by the UPMC hospital Pharmacy and will be given to the
participant by the nursing staff while the participant is in the hospital or to the
care-giver, family member, spouse, an adult child, a family member or adult person
responsible for caring for the subject, if discharged from hospital.
Participation in the experimental treatment protocol will continue until all signs and
symptoms have resolved and ongoing therapy is no longer required to a maximum of 24 months,
or until posaconazole (experimental medication) becomes commercially available (approved by
the FDA). The maximum length of time a subject will be on the investigational medication
will depend on type and severity of the fungal infection, response to the investigational
medication and the discretion of the experimental treatment protocol doctor. For patients
with complete response, posaconazole may be discontinued seven days after resolution of all
signs and symptoms of infection. Subjects with Candida infections of the bloodstream, or
disseminated/metastatic (deep organ) or hepatosplenic candidiasis or endocarditis should be
treated with posaconazole for a minimum of 14 days or at least seven days after resolution
of symptoms.
The experimental treatment use protocol will be carried out at UPMC-Presbyterian hospital.
Subjects will be seen monthly and 30 days after the last dose of investigational medication
to determine how well subjects are responding to the investigational medication.
;
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03641131 -
Ampholipad Real-World Data in Taiwan
|
||
Not yet recruiting |
NCT03292224 -
Systemic Fungal Infections in ICU Patients
|
N/A | |
Completed |
NCT01371656 -
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
|
Phase 3 | |
Completed |
NCT00936117 -
Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia
|
Phase 2 | |
Completed |
NCT00740389 -
TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.
|
Phase 1 | |
Completed |
NCT03857399 -
Empiric Therapy of Patients With Persistent Fever and Agranulocytosis Using Caspofungin
|
Phase 2 | |
Not yet recruiting |
NCT04215458 -
Microbiota in Skin and Mucosa of Patients With Inflammatory Skin Diseases
|
N/A | |
Completed |
NCT03667690 -
Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
|
Phase 3 | |
Completed |
NCT02957929 -
Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally
|
Phase 1 | |
Completed |
NCT01419678 -
Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients
|
N/A | |
Recruiting |
NCT00333645 -
Prophylaxis With Caspofungin in High-Risk Liver Transplantation
|
Phase 2 | |
Not yet recruiting |
NCT03650439 -
Fungal Infections in Patients With Hematological Malignancies
|
||
Completed |
NCT01303549 -
Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients
|
Phase 4 | |
Completed |
NCT00811642 -
Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551)
|
Phase 3 | |
Withdrawn |
NCT00430469 -
Safety of hLF1-11 for the Treatment of Infectious Complications Among HSCT Recipients
|
Phase 1/Phase 2 | |
Terminated |
NCT00386997 -
ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia
|
Phase 4 | |
Completed |
NCT00514358 -
Fluconazole Pharmacokinetics in Infants
|
Phase 1 | |
Completed |
NCT04166669 -
A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001
|
Phase 1 | |
Recruiting |
NCT05150327 -
Multicenter Cohort Study of Invasive Fungal Filamentous Fungal Infections in Liver Transplant Patients
|
||
Completed |
NCT02387983 -
Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117)
|
Phase 1 |